TRCT
PRVL

Tower Research Capital (TRC)’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-838
Closed -$19K – 6042
2020
Q4 		$19K Sell
838
-8,630
-91% -$109K ﹤0.01% 3920
2020
Q3 		$96K Buy
9,468
+5,241
+124% +$70.3K ﹤0.01% 3180
2020
Q2 		$63K Buy
4,227
+2,874
+212% +$44.3K ﹤0.01% 2877
2020
Q1 		$16K Sell
1,353
-2,853
-68% -$45.4K ﹤0.01% 1833
2019
Q4 		$67K Buy
+4,206
New +$53.6K 0.01% 1161
2019
Q3 		– Sell
-614
Closed -$8K – 4753
2019
Q2 		$8K Buy
+614
New +$8.95K ﹤0.01% 2732

Tower Research Capital (TRC)'s PRVL Position: Q1 2021 in Review

Tower Research Capital (TRC) sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 838 shares — an estimated $19K sold.

Tower Research Capital (TRC) first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $96K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Tower Research Capital (TRC) reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 838 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $19K.
  • Tower Research Capital (TRC) first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Prevail Therapeutics Inc. Common Stock position peaked at $96K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.